Trimethoprim-Sulfamethoxazole
Treatment for Cellulitis
Typical Dosage: 160mg TMP/800mg SMX (DS tablet) orally twice daily
Effectiveness
88%
Safety Score
65%
Clinical Trials
10
Participants
40K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
160mg TMP/800mg SMX (DS tablet) orally twice daily
Time to Effect
1-2 days
Treatment Duration
7 days
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15
Monitoring:$125
Side Effect Mgmt:$30
Total Annual:$170
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$188.89
Cost per Remission
$200
Trimethoprim-Sulfamethoxazole Outcomes
for Cellulitis
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Nausea
+7%
Vomiting
+7%
Rash
+4%
Photosensitivity
+7%
Active Clinical Trials
1 active trial recruiting for Trimethoprim-Sulfamethoxazole in Cellulitis
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
NCT06982105RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Indianapolis, United States
Started: May 20, 2025
Completed Clinical Trials
8 completed trials for Trimethoprim-Sulfamethoxazole in Cellulitis
Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients
NCT00676130COMPLETEDNA
153 participants
INTERVENTIONAL
Boston, United States +2 more
Started: May 1, 2007
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
NCT03637400COMPLETEDPHASE2
269 participants
INTERVENTIONAL
Sylmar, United States +2 more
Started: Nov 26, 2018
Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
NCT00829686COMPLETEDNA
31 participants
INTERVENTIONAL
Lackland Air Force Base, United States
Started: Jun 1, 2008
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
NCT00730028COMPLETEDPHASE2
1.31K participants
INTERVENTIONAL
San Francisco, United States +5 more
Started: Apr 1, 2009
Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses
NCT00973765COMPLETEDPHASE3
212 participants
INTERVENTIONAL
Lackland Air Force Base, United States
Started: Nov 1, 2007
Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
NCT00822692COMPLETEDNA
139 participants
INTERVENTIONAL
Lackland Air Force Base, United States
Started: Jul 1, 2008
A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections
NCT01049438COMPLETEDNA
31 participants
INTERVENTIONAL
Started: Aug 1, 2006
Effective Antibiotic Treatment of MRSA
NCT00388310COMPLETEDNA
33 participants
INTERVENTIONAL
Newark, United States
Started: Feb 1, 2006